Clinical application and expectation of amifostine applied during treatment of hematological malignancies
10.3760/cma.j.issn.1009-9921.2009.04.026
- VernacularTitle:氨磷汀在血液肿瘤治疗中的应用与展望
- Author:
Jing REN
;
Hu CHEN
- Publication Type:Journal Article
- Keywords:
Amifostine;
Hematological neoplasms;
Cytoprotection
- From:
Journal of Leukemia & Lymphoma
2009;18(4):252-256
- CountryChina
- Language:Chinese
-
Abstract:
Although hemopoietic stem cell transplant have been used in treating malignant diseases of hematological system using high-dose chemotherapy and radiotherapy before transplant or non-transplant is very important. When the dose of chemotherapy and radiotherapy exceeds the ability the tissues can bear, normal tissue can be badly damaged, which limits the therapeutic efficacy of chemotherapy and radiotherapy. Treatments of hematological malignancies are expected to achieve the best therapeutic efficacy and the least damage of normal cells and tissues. Amifostine is an inorganic thiophosphate eytoprotective agent,its chemname is S-2(3-aminopropyl) amino dihydrogen phosphate.h is a prodrug whose active constitutent is free thiol,it can clears free radicals produced from cytotoxic drugs and radiotherapy in tissues exposed to them. It is a broad-spectrum cytoprotective agent which can protect multifarious normal tissues against damage of chemotherapy and radiotherapy. Using amifostine in proconditioning of hemopoietic stem cell transplant can lessen hematological and renal toxicity, it can also lessen renal toxicity produced by chemotherapeutics as platinum,cyclophosphamide and vincristine. The main purpose of this review is to discuss the cytoprotection of amifostine in hematological malignancies.
